Remifentanil versus alfentanil - Comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers

被引:343
作者
Egan, TD
Minto, CF
Hermann, DJ
Barr, J
Muir, KT
Shafer, SL
机构
[1] UNIV UTAH,SCH MED,SALT LAKE CITY,UT 84112
[2] STANFORD UNIV,SCH MED,STANFORD,CA 94305
[3] GLAXO GRP RES LTD,RES INST,GREENFORD,MIDDX,ENGLAND
[4] VET ADM MED CTR,PALO ALTO,CA 94304
关键词
analgesics; opioids; alfentanil; GI87084B; remifentanil; pharmacokinetics; computer simulations; context-sensitive half-times; population modeling; pharmacodynamics; electroencephalography;
D O I
10.1097/00000542-199604000-00009
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Background: Remifentanil is an esterase-metabolized opioid with a rapid clearance. The aim of this study was to contrast the pharmacokinetics and pharmacodynamics of remifentanil and alfentanil in healthy, adult male volunteers. Methods: Ten volunteers received infusions of remifentanil and alfentanil on separate study sessions using a randomized, open-label crossover design, Arterial blood samples were analyzed to determine drug blood concentrations, The electroencephalogram was employed as the measure of drug effect, The pharmacokinetics were characterized using a moment analysis, a nonlinear mixed effects model (NONMEM) population analysis, and context-sensitive half-time computer simulations, After processing the raw electroencephalogram to obtain the spectral edge parameter, the pharmacodynamics were characterized using an effect compartment, inhibitory maximum effect model. Results Pharmacokinetically, the two drugs are similar in terms of steady-state distribution volume (VDss), but remifentanil's central clearance (CL(c)) is substantially greater. The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CL(c) of 2.91 . min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min, Corresponding NONMEM parameters for alfentanil are 0.361 . min(-1), 34.11, and 94.5 min. Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(eo) for remifentanil of 1.6 min and 0.96 min for alfentanil, However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng . ml(-1) versus 375.9 ng . ml(-1) for alfentanil. Conclusions: Compared to alfentanil, the high clearance of remifentanil, combined with its small steady-state distribution volume, results in a rapid decline in blood concentration after termination of an infusion. With the exception of remifentanil's nearly 20-times greater potency (30-times if alfentanil partitioning between whole blood and plasma is considered), the drugs are pharmacodynamically similar.
引用
收藏
页码:821 / 833
页数:13
相关论文
共 28 条
[1]
THE PHARMACOKINETICS OF ALFENTANIL (R39209) - A NEW OPIOID ANALGESIC [J].
BOVILL, JG ;
SEBEL, PS ;
BLACKBURN, CL ;
HEYKANTS, J .
ANESTHESIOLOGY, 1982, 57 (06) :439-443
[2]
UNDERSTANDING PHARMACOKINETICS AND PHARMACODYNAMICS THROUGH COMPUTER-SIMULATION .1. THE COMPARATIVE CLINICAL PROFILES OF FENTANYL AND ALFENTANIL [J].
EBLING, WF ;
LEE, EN ;
STANSKI, DR .
ANESTHESIOLOGY, 1990, 72 (04) :650-658
[3]
THE PHARMACOKINETICS OF THE NEW SHORT-ACTING OPIOID REMIFENTANIL (GI87084B) IN HEALTHY ADULT MALE-VOLUNTEERS [J].
EGAN, TD ;
LEMMENS, HJM ;
FISET, P ;
HERMANN, DJ ;
MUIR, KT ;
STANSKI, DR ;
SHAFER, SL .
ANESTHESIOLOGY, 1993, 79 (05) :881-892
[4]
DESIGN, SYNTHESIS, AND PHARMACOLOGICAL EVALUATION OF ULTRASHORT-ACTING TO LONG-ACTING OPIOID ANALGESICS [J].
FELDMAN, PL ;
JAMES, MK ;
BRACKEEN, MF ;
BILOTTA, JM ;
SCHUSTER, SV ;
LAHEY, AP ;
LUTZ, MW ;
JOHNSON, MR ;
LEIGHTON, HJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) :2202-2208
[5]
GIBALDI M, 1982, ABSORPTION KINETICS, P145
[6]
GLASS PSA, 1993, ANESTH ANALG, V77, P1031
[7]
DETERMINATION OF REMIFENTANIL IN HUMAN BLOOD BY LIQUID-LIQUID-EXTRACTION AND CAPILLARY GC-HRMS-SIM USING A DEUTERATED INTERNAL STANDARD [J].
GROSSE, CM ;
DAVIS, IM ;
ARRENDALE, RF ;
JERSEY, J ;
AMIN, J .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1994, 12 (02) :195-203
[8]
HENTHORN TK, 1992, AM J PHYSIOL, V262, P903
[9]
UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].
HOLFORD, NHG ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453
[10]
CONTEXT-SENSITIVE HALF-TIME IN MULTICOMPARTMENT PHARMACOKINETIC MODELS FOR INTRAVENOUS ANESTHETIC DRUGS [J].
HUGHES, MA ;
GLASS, PSA ;
JACOBS, JR .
ANESTHESIOLOGY, 1992, 76 (03) :334-341